Screener
Madrigal Pharmaceuticals, Inc. MDGL Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $34,514 | $48,878 |
| Accrued liabilities | 338,656 | 260,392 |
| Operating lease liabilities | 1,034 | 1,018 |
| Total current liabilities | 374,204 | 310,288 |
| Long term liabilities: | ||
| Loan payable, net of discount | 340,794 | 339,881 |
| Operating lease liabilities, net of current portion | 5,923 | 6,731 |
| Total long term liabilities | 346,717 | 346,612 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s total current liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total current liabilities of $374.2M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total current liabilities increased by 90.4% year-over-year, from $196.5M to $374.2M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total current liabilities has grown at a 46.1% compound annual growth rate (CAGR), from $46.56M to $310.29M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude